×




Eli Lilly: Developing Cymbalta Net Present Value (NPV) / MBA Resources

Introduction to Net Present Value (NPV) - What is Net Present Value (NPV) ? How it impacts financial decisions regarding project management?

NPV solution for Eli Lilly: Developing Cymbalta case study


At Oak Spring University, we provide corporate level professional Net Present Value (NPV) case study solution. Eli Lilly: Developing Cymbalta case study is a Harvard Business School (HBR) case study written by Elie Ofek, Ron Laufer. The Eli Lilly: Developing Cymbalta (referred as “Cymbalta Treating” from here on) case study provides evaluation & decision scenario in field of Sales & Marketing. It also touches upon business topics such as - Value proposition, Marketing, Pricing, Product development.

The net present value (NPV) of an investment proposal is the present value of the proposal’s net cash flows less the proposal’s initial cash outflow. If a project’s NPV is greater than or equal to zero, the project should be accepted.

NPV = Present Value of Future Cash Flows LESS Project’s Initial Investment






Case Description of Eli Lilly: Developing Cymbalta Case Study


Anticipating the expiration of its Prozac patent, Eli Lilly has to make tough decisions regarding the development of its next-generation antidepressant drug. In particular, the company needs to decide whether to first establish that once-a-day dosing for Cymbalta (Duloxetine) is effective in treating major depressive disorder and only after launch get FDA approval for treating painful physical symptoms, or to first establish efficacy in treating pain and later get FDA approval for once-a-day dosing. The decision needs to take into account how Cymbalta can be differentiated in the marketplace vis-a-vis other antidepressants and the marketing challenges to getting adoption that the new drug will face. Lilly's new antidepressant team making this decision has several market research inputs on physicians and patients at its disposal.


Case Authors : Elie Ofek, Ron Laufer

Topic : Sales & Marketing

Related Areas : Marketing, Pricing, Product development




Calculating Net Present Value (NPV) at 6% for Eli Lilly: Developing Cymbalta Case Study


Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 6 %
Discounted
Cash Flows
Year 0 (10007420) -10007420 - -
Year 1 3456972 -6550448 3456972 0.9434 3261294
Year 2 3961451 -2588997 7418423 0.89 3525677
Year 3 3964007 1375010 11382430 0.8396 3328257
Year 4 3229612 4604622 14612042 0.7921 2558155
TOTAL 14612042 12673384




The Net Present Value at 6% discount rate is 2665964

In isolation the NPV number doesn't mean much but put in right context then it is one of the best method to evaluate project returns. In this article we will cover -

Different methods of capital budgeting


What is NPV & Formula of NPV,
How it is calculated,
How to use NPV number for project evaluation, and
Scenario Planning given risks and management priorities.




Capital Budgeting Approaches

Methods of Capital Budgeting


There are four types of capital budgeting techniques that are widely used in the corporate world –

1. Profitability Index
2. Payback Period
3. Net Present Value
4. Internal Rate of Return

Apart from the Payback period method which is an additive method, rest of the methods are based on Discounted Cash Flow technique. Even though cash flow can be calculated based on the nature of the project, for the simplicity of the article we are assuming that all the expected cash flows are realized at the end of the year.

Discounted Cash Flow approaches provide a more objective basis for evaluating and selecting investment projects. They take into consideration both –

1. Timing of the expected cash flows – stockholders of Cymbalta Treating have higher preference for cash returns over 4-5 years rather than 10-15 years given the nature of the volatility in the industry.
2. Magnitude of both incoming and outgoing cash flows – Projects can be capital intensive, time intensive, or both. Cymbalta Treating shareholders have preference for diversified projects investment rather than prospective high income from a single capital intensive project.






Formula and Steps to Calculate Net Present Value (NPV) of Eli Lilly: Developing Cymbalta

NPV = Net Cash In Flowt1 / (1+r)t1 + Net Cash In Flowt2 / (1+r)t2 + … Net Cash In Flowtn / (1+r)tn
Less Net Cash Out Flowt0 / (1+r)t0

Where t = time period, in this case year 1, year 2 and so on.
r = discount rate or return that could be earned using other safe proposition such as fixed deposit or treasury bond rate. Net Cash In Flow – What the firm will get each year.
Net Cash Out Flow – What the firm needs to invest initially in the project.

Step 1 – Understand the nature of the project and calculate cash flow for each year.
Step 2 – Discount those cash flow based on the discount rate.
Step 3 – Add all the discounted cash flow.
Step 4 – Selection of the project

Why Sales & Marketing Managers need to know Financial Tools such as Net Present Value (NPV)?

In our daily workplace we often come across people and colleagues who are just focused on their core competency and targets they have to deliver. For example marketing managers at Cymbalta Treating often design programs whose objective is to drive brand awareness and customer reach. But how that 30 point increase in brand awareness or 10 point increase in customer touch points will result into shareholders’ value is not specified.

To overcome such scenarios managers at Cymbalta Treating needs to not only know the financial aspect of project management but also needs to have tools to integrate them into part of the project development and monitoring plan.

Calculating Net Present Value (NPV) at 15%

After working through various assumptions we reached a conclusion that risk is far higher than 6%. In a reasonably stable industry with weak competition - 15% discount rate can be a good benchmark.



Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 15 %
Discounted
Cash Flows
Year 0 (10007420) -10007420 - -
Year 1 3456972 -6550448 3456972 0.8696 3006063
Year 2 3961451 -2588997 7418423 0.7561 2995426
Year 3 3964007 1375010 11382430 0.6575 2606399
Year 4 3229612 4604622 14612042 0.5718 1846541
TOTAL 10454429


The Net NPV after 4 years is 447009

(10454429 - 10007420 )








Calculating Net Present Value (NPV) at 20%


If the risk component is high in the industry then we should go for a higher hurdle rate / discount rate of 20%.

Years              Cash Flow     Net Cash Flow     Cumulative    
Cash Flow
Discount Rate
@ 20 %
Discounted
Cash Flows
Year 0 (10007420) -10007420 - -
Year 1 3456972 -6550448 3456972 0.8333 2880810
Year 2 3961451 -2588997 7418423 0.6944 2751008
Year 3 3964007 1375010 11382430 0.5787 2293986
Year 4 3229612 4604622 14612042 0.4823 1557490
TOTAL 9483294


The Net NPV after 4 years is -524126

At 20% discount rate the NPV is negative (9483294 - 10007420 ) so ideally we can't select the project if macro and micro factors don't allow financial managers of Cymbalta Treating to discount cash flow at lower discount rates such as 15%.





Acceptance Criteria of a Project based on NPV

Simplest Approach – If the investment project of Cymbalta Treating has a NPV value higher than Zero then finance managers at Cymbalta Treating can ACCEPT the project, otherwise they can reject the project. This means that project will deliver higher returns over the period of time than any alternate investment strategy.

In theory if the required rate of return or discount rate is chosen correctly by finance managers at Cymbalta Treating, then the stock price of the Cymbalta Treating should change by same amount of the NPV. In real world we know that share price also reflects various other factors that can be related to both macro and micro environment.

In the same vein – accepting the project with zero NPV should result in stagnant share price. Finance managers use discount rates as a measure of risk components in the project execution process.

Sensitivity Analysis

Project selection is often a far more complex decision than just choosing it based on the NPV number. Finance managers at Cymbalta Treating should conduct a sensitivity analysis to better understand not only the inherent risk of the projects but also how those risks can be either factored in or mitigated during the project execution. Sensitivity analysis helps in –

What will be a multi year spillover effect of various taxation regulations.

What are the key aspects of the projects that need to be monitored, refined, and retuned for continuous delivery of projected cash flows.

What can impact the cash flow of the project.

What are the uncertainties surrounding the project Initial Cash Outlay (ICO’s). ICO’s often have several different components such as land, machinery, building, and other equipment.

Understanding of risks involved in the project.

Some of the assumptions while using the Discounted Cash Flow Methods –

Projects are assumed to be Mutually Exclusive – This is seldom the came in modern day giant organizations where projects are often inter-related and rejecting a project solely based on NPV can result in sunk cost from a related project.

Independent projects have independent cash flows – As explained in the marketing project – though the project may look independent but in reality it is not as the brand awareness project can be closely associated with the spending on sales promotions and product specific advertising.






Negotiation Strategy of Eli Lilly: Developing Cymbalta

References & Further Readings

Elie Ofek, Ron Laufer (2018), "Eli Lilly: Developing Cymbalta Harvard Business Review Case Study. Published by HBR Publications.


Iress SWOT Analysis / TOWS Matrix

Technology , Software & Programming


Sanyodo SWOT Analysis / TOWS Matrix

Services , Retail (Specialty)


Perfect Optronics Ltd SWOT Analysis / TOWS Matrix

Technology , Electronic Instr. & Controls


Equita SWOT Analysis / TOWS Matrix

Financial , Investment Services


AJ Greentech SWOT Analysis / TOWS Matrix

Basic Materials , Chemical Manufacturing


Applied Genetic SWOT Analysis / TOWS Matrix

Healthcare , Biotechnology & Drugs


Eurazeo SWOT Analysis / TOWS Matrix

Financial , Misc. Financial Services